Stay updated on PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Sign up to get notified when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.

Latest updates to the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now shows a new revision label: v3.3.2 replaces the previous v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRemoved the government funding status notice banner at the top of the page; the study details, eligibility criteria, and contacts remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check34 days agoChange DetectedThe page layout has been updated visually, but the study details and eligibility criteria remain unchanged.SummaryDifference0.2%

- Check63 days agoChange DetectedUpdated version to v3.2.0 and removed a specific resource topic (Medullary thyroid carcinoma) from the Genetic and Rare Diseases Information Center resources; added a government operating-status notice.SummaryDifference6%

- Check70 days agoChange DetectedRenamed a medical condition term (Medullary thyroid gland carcinoma → Medullary thyroid carcinoma) and updated the revision/version to v3.1.0.SummaryDifference0.2%

- Check84 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2, and the 'Back to Top' element was removed.SummaryDifference0.3%

Stay in the know with updates to PAAP for Pralsetinib in NSCLC and MTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PAAP for Pralsetinib in NSCLC and MTC Clinical Trial page.